References
- Bledsoe JR, Redd RA, Hasserjian RP, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol. 2016;91:E436–441.
- Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.
- Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032.
- Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015;125:33–39.
- Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84:1361–1392.
- Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–327.
- Romero M, Gapihan G, Castro-Vega LJ, et al. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. Oncotarget. 2017;8:16243–16258.
- Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2008;2008:349–358.
- Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology. 1986;10:379–390.
- Lamarre L, Jacobson JO, Aisenberg AC, et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730–739.
- Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659–2669.
- Martelli M, Di Rocco A, Russo E, et al. Primary mediastinal lymphoma: diagnosis and treatment options. Expert Rev Hematol. 2015;8:173–186.
- Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258–1264.
- Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–1416.
- Aoki T, Shimada K, Suzuki R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J. 2015;5:e372.
- Petkovic I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19:428–435.
- National Comprehensive Cancer Network. NCCN guidelines: B-cell lymphomas. 2017 [cited 2018 Aug 10].; Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#site
- Ahn HJ, Yoon DH, Kim S, et al. Primary mediastinal large B-cell lymphoma: a single-center experience in Korea. Blood Res. 2014;49:36–41.
- Diumenjo MC, Abriata G, Forman D, et al. The burden of non-Hodgkin lymphoma in Central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S168–s177.
- Giri S, Bhatt VR, Pathak R, et al. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis. Am J Hematol. 2015;90:1052–1054.
- Jackson MW, Rusthoven CG, Jones BL, et al. Improved survival with radiation therapy in stage I-II primary mediastinal B cell lymphoma: a surveillance, epidemiology, and end results database analysis. Int J Radiat Oncol Biol Phys. 2016;94:126–132.
- Liu PP, Wang KF, Xia Y, et al. Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis. Medicine (Baltimore). 2016;95:e4054.
- Szumera-Cieckiewicz A, Galazka K, Szpor J, et al. Distribution of lymphomas in Poland according to World Health Organization classification: analysis of 11718 cases from national histopathological lymphoma register project - the Polish Lymphoma Research Group study. Int J Clin Exp Pathol. 2014;7:3280–3286.
- Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
- Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9:381–385.
- Surveillance E, and End Results (SEER). SEER database report 2004–2010. 2010 [cited 2018 Oct 3]; Available from: https://seer.cancer.gov/#skipnav
- Surveillance E, and End Results (SEER). SEER database report 2002–2011. 2011 [cited 2018 Oct 3]; Available from: https://seer.cancer.gov/#skipnav
- Aoki T, Izutsu K, Suzuki R, et al. Novel prognostic model of primary mediastinal large B-cell lymphoma (PMBL): a multicenter cooperative retrospective study in Japan. Am Soc Hematol. 2013;122:638.
- Australian Cancer Network. Clinical Practice guidelines for the diagnosis and management of lymphoma. 2005 [cited 2018 Aug 10]; Available from: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp107_diagnosis_management_lymphoma_150616.pdf
- Verhoef G, Schroyens W, Bron D, et al. Guidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL. Belg J Hematol. 2013;4:51–57.
- Cancer Centre of Southeastern Ontario. Aggressive B non-Hodgkin’s lymphoma standard management guidelines. 2016 [cited 2018 Aug 10]; Available from: http://oncology.queensu.ca/assets/DISEASE_SI0TE_GUIDELINES/Aggressive_B_non-Hodgkins_Lymphoma_CCSEOStandardManagementGuidelines_V1.3.1_2016-08-30.pdf
- Crump M. Princess margaret cancer centre clinical practice guidelines. 2015 [cited 2018 Aug 10]; Available from: https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Central_Nervous_System_Eye/Documents/CPG_Ocular_%20PeriocularCutaneousMalignancy.pdf
- Zinzani PL, Martelli M, Poletti V, et al. Practice guidelines for the management of extranodal non-Hodgkin’s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian society of hematology, the Italian society of experimental hematology and the Italian group for bone marrow transplantation. Haematologica. 2008;93:1364–1371.
- Lymphoma Forum of Ireland. Guidelines on diagnosis and treatment of malignant lymphomas. 2010 [cited 2018 Aug 10]; Available from: http://www.haematologyireland.ie/wp-content/uploads/2016/03/Lymphoma-GuidelinesonDiagnosisandTreatmentofMalignantLymphomas.pdf
- Cwynarski K. Guidelines for the management of non‐Hodgkin’s and Hodgkin’s lymphoma in adults. 2015 [cited 2018 Aug 10]; Available from: http://www.londoncancer.org/media/134135/Lymphoma-_London-Cancer-Guidelines-2015.pdf
- London Cancer Alliance. LCA haemato-oncology clinical guidelines. 2015 [cited 2018 Aug 10]; Available from: http://rmpartners.cancervanguard.nhs.uk/wp-content/uploads/2017/03/lca-follicular-lymphoma-clinical-guidelines-august-2015.pdf
- South Wales Cancer Network. Guidelines for the management of aggressive non Hodgkin lymphomas in adults. 2015 [cited 2018 Aug 10]; Available from: www.cancerservicesdirectory.wales.nhs.uk/opendoc/285261
- MD Anderson Cancer Center. Primary mediastinal large B-cell lymphoma. 2017 [cited 2018 Aug 10]; Available from: https://www.mdanderson.org/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-lymphoma-pmlbc-web-algorithm.pdf
- Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v91–v102.
- Jung H, Sang-hun L, Yoo HS, et al. Clinical practice guidelines of Korean medicine for malignant lymphoma. J Int Korean Med. 2016;37:453–466.
- Armatys A, Szcześniak M, Helbig G, et al. The outcome of primary mediastinal B-cell lymphoma in a single center experience. Acta Haematol Pol. 2015;46:56–60.
- Broccoli A, Casadei B, Stefoni V, et al. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. BMC Cancer. 2017;17:276.
- Falorio S, Fioritoni F, Ferrara F, et al. Good outcome of refractory patients affected by primary mediastinal B-cell lymphoma treated with peripheral blood stem cell autografting. Bone Marrow Transplant. 2010;45:S246.
- Hamlin PA, Dickson M, Kewalramani T, et al. Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: outcome with ICE-based treatment. Blood. 2006;108:3057.
- Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial sloan kettering from 1980 to 1999. Br J Haematol. 2005;130:691–699.
- Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:1329–1336.
- Massoud M, Koscielny S, Lapusan S, et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma. 2008;49:1510–1515.
- Nguyen LN, Ha CS, Hess M, et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys. 2000;47:1281–1285.
- Pinnix CC, Dabaja B, Ahmed MA, et al. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015;92:113–121.
- Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123–130.
- Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998;91:717–723.
- Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55:538–543.
- Tavares M, Simas AM, Castro C, et al. Treatment outcomes of patients with primary mediastinal diffuse large B-cell lymphoma: a single-center experience. J Hematol Thrombo Dis. 2015;3:5.
- Nath SV, Seymour JF. Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leuk Lymphoma. 2005;46:1075–1079.
- Bhatt VR, Mourya R, Shrestha R, et al. Primary mediastinal large B-cell lymphoma. Cancer Treat Rev. 2015;41:476–485.
- Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017;2017:298–303.
- Dunleavy K, Steidl C. Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. Semin Hematol. 2015;52:119–125.
- Zinzani PL, Broccoli A. Optimizing outcomes in primary mediastinal B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30:1261–1275.
- Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604–616.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
- Kocurek A, Malkowski B, Giza A, et al. Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy. Contemp Oncol (Pozn). 2016;20:297–301.
- Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;100:652–669.
- Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.